Krzysztof Selmaj

University of Warmia and Mazury in Olsztyn
Poland

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 75 Citations 31,408 412 World Ranking 14297 National Ranking 18

Research.com Recognitions

Awards & Achievements

1994 - Prize of the Foundation for Polish Science - Nagroda Fundacji na rzecz Nauki Polskiej for his studies into new immunological mechanisms in autoimmune diseases of the nervous system, Multiple Sclerosis in particular

Overview

What is he best known for?

The fields of study Krzysztof Selmaj is best known for:

Cytokine
Immune system
Central nervous system

Krzysztof Selmaj brings together Central nervous system and Experimental autoimmune encephalomyelitis to produce work in his papers. He merges many fields, such as Experimental autoimmune encephalomyelitis and Encephalomyelitis, in his writings. His work blends Encephalomyelitis and Multiple sclerosis studies together. He undertakes interdisciplinary study in the fields of Multiple sclerosis and Lesion through his works. He integrates Lesion with Pathology in his research. While working on this project, he studies both Pathology and Internal medicine. As part of his studies on Internal medicine, Krzysztof Selmaj often connects relevant subjects like Microglia. He combines Microglia and Central nervous system in his research. His Immunology study frequently links to related topics such as Spleen.

His most cited work include:

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. (689 citations)
Anti?tumor necrosis factor therapy abrogates autoimmune demyelination (416 citations)
Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004* (289 citations)

What are the main themes of his work throughout his whole career to date

As part of his inquiry into Fingolimod and Relapsing remitting, Krzysztof Selmaj is doing Multiple sclerosis research. As part of his Peripheral blood mononuclear cell, Cytotoxicity and Cytotoxic T cell and In vitro studies, he is studying In vitro. His work on Spleen expands to the thematically related Immunology. Krzysztof Selmaj frequently studies issues relating to Adverse effect and Internal medicine. His study deals with a combination of Pathology and Gastroenterology. Krzysztof Selmaj conducts interdisciplinary study in the fields of Gastroenterology and Pathology through his works. He undertakes interdisciplinary study in the fields of Tumor necrosis factor alpha and Lymphotoxin through his research. His study brings together the fields of Stimulation and Endocrinology. His Endocrinology research extends to the thematically linked field of Stimulation.

Krzysztof Selmaj most often published in these fields:

Immunology (81.82%)
Multiple sclerosis (77.27%)
Internal medicine (63.64%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Ludwig Kappos;Ernst Wilhelm Radue;Paul O'Connor;Chris Polman.
The New England Journal of Medicine (2010)

2939 Citations

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Stephen Sawcer;Garrett Hellenthal;Matti Pirinen;Chris C. A. Spencer.
Nature (2011)

2667 Citations

Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro

Krzysztof W. Selmaj;Cedric S. Raine.
Annals of Neurology (1988)

2071 Citations

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Ralf Gold;Ludwig Kappos;Douglas L Arnold;Amit Bar-Or.
The New England Journal of Medicine (2012)

1767 Citations

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold.
The New England Journal of Medicine (2017)

1371 Citations

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni.
The New England Journal of Medicine (2017)

1263 Citations

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial

Alasdair J. Coles;Cary L. Twyman;Douglas L. Arnold;Jeffrey A. Cohen.
The Lancet (2012)

1091 Citations

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Jeffrey A. Cohen;Alasdair J. Coles;Douglas L. Arnold;Christian Confavreux.
The Lancet (2012)

1081 Citations

Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions.

K Selmaj;C S Raine;B Cannella;C F Brosnan.
Journal of Clinical Investigation (1991)

1077 Citations

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Camms Trial Investigators;Alasdair J Coles;D Alastair S Compston;Krzysztof W Selmaj.
The New England Journal of Medicine (2008)

964 Citations

If you think any of the details on this page are incorrect, let us know.